(NASDAQ: ADPT) Adaptive Biotechnologies's forecast annual revenue growth rate of 8.44% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 99.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.58%.
Adaptive Biotechnologies's revenue in 2025 is $252,754,000.On average, 10 Wall Street analysts forecast ADPT's revenue for 2025 to be $41,202,807,589, with the lowest ADPT revenue forecast at $39,347,925,555, and the highest ADPT revenue forecast at $42,767,625,766. On average, 10 Wall Street analysts forecast ADPT's revenue for 2026 to be $41,683,702,932, with the lowest ADPT revenue forecast at $38,256,369,461, and the highest ADPT revenue forecast at $44,162,985,585.
In 2027, ADPT is forecast to generate $50,765,754,966 in revenue, with the lowest revenue forecast at $46,962,865,133 and the highest revenue forecast at $54,725,889,942.